Skip to main content

Advertisement

SpringerLink
Log in

The Clinical Significance of Serum Soluble Fas and p53 Protein in Breast Cancer Patients: Comparison with Serum CA 15-3

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Serum sFas and p53 protein have been observed in breast cancer patients, but their clinical usefulness for diagnosis and therapy monitoring has not been clarified. The aim of this study was to compare the clinical utility of serum sFas and p53 protein with that of serum CA 15-3 as the most commonly used breast cancer tumor marker. Serum samples were taken from 35 normal healthy controls and 35 breast cancer patients before surgery, after 2 weeks of surgery and after six cycles of FAC chemotherapy. Serum sFas and p53 protein levels were measured using ELISA kits. Serum CA 15-3 levels were determined using IRMA kit. Mean Serum levels of sFas and CA 15-3 were significantly elevated while p53 protein was significantly declined in breast caner patients than controls. Serum p53 protein showed the greatest significant area under the ROC curve (84.3%) followed by sFas (80.5%), then CA 15-3 (78%). The sensitivity, specificity and cut-off value for diagnosing breast cancer patients were 84.2%, 82.6% and 2.88 U/ml for p53 protein, 83.3%, 68.2% and 497.3 pg/ml for sFas and 45.8%, 100% and 23 U/ml for CA15-3. Surgical removal of breast resulted in a significant decline in serum sFas level with no effect on serum p53 protein and CA 15-3 levels. Six cycles of chemotherapy resulted in a significant elevation in serum sFas level with no effect on serum p53 protein and CA 15-3 levels. sFas was significantly correlated with tumor grade. It could be concluded that although serum p53 protein is superior to sFas and CA15-3 for diagnosis of breast cancer patients, only sFas is useful for monitoring the response of breast cancer patients to surgery and chemotherapy if the effect of systemic inflammatory reactions is excluded.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Tamakoshi 1A, Nakachi K, Ito Y, Lin Y, Yagyu K, Kikuchi 1S, et al (2008) Soluble Fas level and cancer mortality: Findings from a nested case–control study within a large-scale prospective study. Int. J. Cancer 123: 1913–1916.

  2. Sheen-Chen SM, Chen HS, Eng HL, Chenw J (2003) Circulating soluble Fas in patients with breast cancer. World J Surg 27:10–13

    Article  PubMed  Google Scholar 

  3. Jager J, Jansen R, Arends J (2002) Clinical relevance of apoptotic markers in breast cancer not yet clear. Apoptosis 7:361–365

    Article  PubMed  CAS  Google Scholar 

  4. Evan G, Littlewood T (1998) A matter of life and cell death. Science 94:695–698

    Google Scholar 

  5. Kolomecki K, Maciaszczyk P, Stepien T, Kuzdak K, Ulanska J (2005) p53 concentration and soluble FasL(sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors. Bratisl Lek Listy 106:297–300

    PubMed  CAS  Google Scholar 

  6. Bennett M, Macdonald K, Chen SW, Luzio JP, Simari R, Weissberg P (1998) Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282:290–293

    Article  PubMed  CAS  Google Scholar 

  7. Balogh GA, Mailo DA, Corte MM, Roncoroni P, Nardi H, Vincen E et al (2006) Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol 28:995–1002

    PubMed  CAS  Google Scholar 

  8. Duffy MJ (1999) CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579–586

    PubMed  CAS  Google Scholar 

  9. Keyhani M, Nasizadeh S, Dehghannejad A (2005) Serum CA 15-3 measurment in breast cancer patients before and after mastectomy. Arch Iranian Med 8:263–266

    Google Scholar 

  10. Haskell CM, Lowitz BB, Casciato AD (1985) Breast cancer. In: Casciato AD, Lowitz BB (eds) Manual of clinical oncology, 2nd edn. Little and Brown, Boston, pp 150–165

    Google Scholar 

  11. Rintoul RF (1986) Operations on the breast. In: Farquhaerison,s text book of operative surgery, 7th ed. Churchill living stone (pub.) 270-281

  12. Abeloff MD, Lichter AS, Niederhuber JE, Pierce LJ, Aziz DC (1995) Breast. In: Abeloff MD, Armitage JO, Licher AS, Niederhuber JE (eds) Clinical Oncology, Churchil livingstone Inc. (Pub.) 1617–714

  13. Munakata S, Watanabe O, Ohashi K, Morino H (2005) Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am J Clin pathol 123:879–885

    Article  PubMed  CAS  Google Scholar 

  14. Zhang L, Levi E, Majumder P, Yu Y, Aboukameel A, Du J (2007) Transactivator of transcription tagged cell cycle and apoptosis regulatory protein-1 peptides suppress the growth of human breast cancer cells in vitro and in vivo. Mol cancer Ther 6:1661–1672

    Article  PubMed  CAS  Google Scholar 

  15. Motyl T, Gajkowska B, Zarzy J, Gajewska M, Lamparska P (2006) Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol 7:17–32

    Google Scholar 

  16. Habibagahi M, Jaberipour M, Fattahi MJ, Hashemi SB, Shariati M (2010) High concentration of serum soluble Fas in patients with head and neck carcinoma: a comparative study before and after surgical removal of tumor. Middle East J Can 1:21–26

    Google Scholar 

  17. El-Sarha A, Magour G, Zaki S, El-Sammak M (2009) Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma. Pathol Oncol Res 15:241–250

    Article  PubMed  CAS  Google Scholar 

  18. Ohbu M, Saegusa M, Okayasu I (1995) Apoptosis and cellular proliferation in oesophageal squamous cell carcinoma: differences between keratinizing and nonkeratinizing types. Virchows arch 427:271–276

    Article  PubMed  CAS  Google Scholar 

  19. Pignataro L, Arisi E, Sambataro G, Corsi MM (2003) Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment. J Sur Oncol 83:112–115

    Article  CAS  Google Scholar 

  20. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased soluble CD95(sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 7:1282–1286

    PubMed  CAS  Google Scholar 

  21. Shimizu M, Kondo M, Ito Y, Kume H, Suzuki R, Yamaki K (2005) Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Canc Detect Prev 29:175–180

    Article  CAS  Google Scholar 

  22. Iwase M, Kondo G, Watanabe H, Takaoka S, Uchida M, Ohashi M et al (2006) Regulation of Fas-mediated apoptosis in neutrophils after surgery-induced acute inflammation. J Surg Res 134:114–123

    Article  PubMed  CAS  Google Scholar 

  23. Paunel-Gorgulu A, Flohe S, Scholz M, Windolf J, Logters T (2011) Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis. Critical care 15:R20

    Article  PubMed  Google Scholar 

  24. Donnelly SC, MacGregor I, Zamani A, Gordon MW, Robertson CE, Steedman DJ et al (1995) Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med 151:1428–1433

    PubMed  CAS  Google Scholar 

  25. Bhatia R, Dent C, Topley N, Pallister I (2006) Neutrophil priming for elastase release in adult blunt trauma patients. J Trauma 60:590–596

    Article  PubMed  CAS  Google Scholar 

  26. Nadal C, Maurel J, Gallego R, Castells A, Longarón R, Marmol M et al (2005) Fas/Fas ligand ratio: a marker of Oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. Clin Cancer Res 11:4770–4774

    Article  PubMed  CAS  Google Scholar 

  27. Hewala TI, Abd EL-Moneim NA, Ebied SA, Sheta MI, Soliman K, Abu-ELenean A (2010) Diagnostic and prognostic value of serum nitric oxide, tumor necrosis factor-a, basic fibroblast growth factor and copper as angiogenic markers in premenopausal breast cancer patients: a case-control study. BJBS 67:167–176

    CAS  Google Scholar 

  28. Gion M, Mione R, Leon AE, Dittadi R (1999) Comparison of the diagnostic accuracy of CA27.29 and CA15-3 in primary breast cancer. Clin Chem 45:630–637

    PubMed  CAS  Google Scholar 

  29. Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345–351

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Sciences, Medical Research Institute, Alexandria University, 165 El-Horria Avenue, El Hadara, Alexandria, 21561, Egypt

    Taha I. Hewala

  2. Department of Cancer Management and Research, Medical Research Institute, Alexandria University, 165 El-Horria Avenue, El Hadara, Alexandria, 21561, Egypt

    Nadia A. Abd El-Monaim

  3. Department of Experimental and Clinical Surgery, Medical Research Institute, Alexandria University, 165 El-Horria Avenue, El Hadara, Alexandria, 21561, Egypt

    Medhat Anwar

  4. Department of Applied Medical Chemistry, Medical Research Institute, Alexandria University, 165 El-Horria Avenue, El Hadara, Alexandria, 21561, Egypt

    Samia A. Ebied

Authors
  1. Taha I. Hewala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadia A. Abd El-Monaim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Medhat Anwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samia A. Ebied
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taha I. Hewala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hewala, T.I., Abd El-Monaim, N.A., Anwar, M. et al. The Clinical Significance of Serum Soluble Fas and p53 Protein in Breast Cancer Patients: Comparison with Serum CA 15-3. Pathol. Oncol. Res. 18, 841–848 (2012). https://doi.org/10.1007/s12253-012-9512-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-012-9512-1

Keywords

Search

Navigation